AE37: a novel T-cell-eliciting vaccine for breast cancer-Reference-Cited by-同舟云学术

AE37: a novel T-cell-eliciting vaccine for breast cancer

Published:2011-09-06 Issue:11 Volume:11 Page:1543-1550
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Sears Alan K,Perez Sonia A,Clifton Guy T,Benavides Linda C,Gates Jeremy D,Clive Kevin S,Holmes Jarrod P,Shumway Nathan M,Van Echo David C,Carmichael Mark G,Ponniah Sathibalan,Baxevanis Constantin N,Mittendorf Elizabeth A,Papamichail Michael,Peoples George E

Publisher

Informa Healthcare

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

http://www.tandfonline.com/doi/pdf/10.1517/14712598.2011.616889

Reference29 articles.

1. Breast cancer vaccines

2. HER2: Biology, Detection, and Clinical Implications

3. Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer

4. Use of monoclonal antibodies in the treatment of ovarian cancer

5. HER-2/ neu Expression in Prostate Adenocarcinoma: A Systematic Review and Meta-Analysis

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Peptide Vaccines in Breast Cancer;Cancer Immunotherapy;2024

2. AE37 HER2-targeted vaccine in the prevention of breast cancer recurrence: A mini narrative review of current evidence;Medicine;2023-12-29

3. Creation and characterization of a recombinant mammalian orthoreovirus expressing σ1 fusion proteins encoding human epidermal growth factor receptor 2 peptides;Virology;2023-10

4. Navigating the Blood–Brain Barrier: Challenges and Therapeutic Strategies in Breast Cancer Brain Metastases;International Journal of Molecular Sciences;2023-07-27

5. CREATION AND CHARACTERIZATION OF A RECOMBINANT MAMMALIAN ORTHOREOVIRUS EXPRESSING HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 PEPTIDES;2023-06-13